We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. 

We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.

We are a focused biopharma company. We prevent and treat disease with vaccines, specialty and general medicines. We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology. Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems. 

We’re uniting science, technology and talent to make a difference in more people’s lives. We don’t just want to find new, better medicines and vaccines. By harnessing our science and technology, we have an opportunity to prevent disease in the first place, as well as change the course of a disease – helping to prevent or slow progression of an illness and limit long-term complications. Our broad portfolio and pipeline continues  to strengthen, with key milestones across our core therapeutic areas in 2023. Strategic partnerships are critical to opening up new avenues of discovery. We have important collaborations, including with the University of Oxford on neurodegenerative diseases, Kings College London on cancer treatment and 23andMe on genetics and genomics.